Selective loss of function variants in IL6ST cause Hyper-IgE syndrome with distinct impairments of T-cell phenotype and function
Tala Shahin,
Dominik Aschenbrenner,
Deniz Cagdas,
Sevgi Köstel Bal,
Cecilia Domínguez Conde,
Wojciech Garncarz,
David Medgyesi,
Tobias Schwerd,
Betül Karaatmaca,
Pınar Gur Cetinkaya,
Saliha Esenboga,
Stephen R. F. Twigg,
Andrew Cant,
Andrew O. M. Wilkie,
Ilhan Tezcan,
Holm H. Uhlig,
Kaan Boztug
Affiliations
Tala Shahin
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria;CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
Dominik Aschenbrenner
Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, UK
Deniz Cagdas
Section of Pediatric Immunology, Ihsan Doğramacı Children’s Hospital, Hacettepe University, Ankara, Turkey;Institute of Child Health, Hacettepe University, Ankara, Turkey
Sevgi Köstel Bal
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria;CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;Department of Pediatric Allergy and Immunology, Ankara University School of Medicine, Cebeci, Turkey
Cecilia Domínguez Conde
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria;CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
Wojciech Garncarz
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria;CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
David Medgyesi
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria;CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
Tobias Schwerd
Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, UK;Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University of Munich, Germany
Betül Karaatmaca
Section of Pediatric Immunology, Ihsan Doğramacı Children’s Hospital, Hacettepe University, Ankara, Turkey
Pınar Gur Cetinkaya
Section of Pediatric Immunology, Ihsan Doğramacı Children’s Hospital, Hacettepe University, Ankara, Turkey
Saliha Esenboga
Section of Pediatric Immunology, Ihsan Doğramacı Children’s Hospital, Hacettepe University, Ankara, Turkey
Stephen R. F. Twigg
Clinical Genetics Group, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK
Andrew Cant
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
Andrew O. M. Wilkie
Clinical Genetics Group, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK
Ilhan Tezcan
Section of Pediatric Immunology, Ihsan Doğramacı Children’s Hospital, Hacettepe University, Ankara, Turkey;Institute of Child Health, Hacettepe University, Ankara, Turkey
Holm H. Uhlig
Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, UK;Department of Paediatrics, University of Oxford, UK
Kaan Boztug
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria;CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Austria;St. Anna Kinderspital and Children’s Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Austria
Hyper-IgE syndromes comprise a group of inborn errors of immunity. STAT3-deficient hyper-IgE syndrome is characterized by elevated serum IgE levels, recurrent infections and eczema, and characteristic skeletal anomalies. A loss-of-function biallelic mutation in IL6ST encoding the GP130 receptor subunit (p.N404Y) has very recently been identified in a singleton patient (herein referred to as PN404Y) as a novel etiology of hyper-IgE syndrome. Here, we studied a patient with hyper-IgE syndrome caused by a novel homozygous mutation in IL6ST (p.P498L; patient herein referred to as PP498L) leading to abrogated GP130 signaling after stimulation with IL-6 and IL-27 in peripheral blood mononuclear cells as well as IL-6 and IL-11 in fibroblasts. Extending the initial identification of selective GP130 deficiency, we aimed to dissect the effects of aberrant cytokine signaling on T-helper cell differentiation in both patients. Our results reveal the importance of IL-6 signaling for the development of CCR6-expressing memory CD4+ T cells (including T-helper 17-enriched subsets) and non-conventional CD8+T cells which were reduced in both patients. Downstream functional analysis of the GP130 mutants (p.N404Y and p.P498L) have shown differences in response to IL-27, with the p.P498L mutation having a more severe effect that is reflected by reduced T-helper 1 cells in this patient (PP498L) only. Collectively, our data suggest that characteristic features of GP130-deficient hyper-IgE syndrome phenotype are IL-6 and IL-11 dominated, and indicate selective roles of aberrant IL-6 and IL-27 signaling on the differentiation of T-cell subsets.